Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse® in Ambulatory Patients SMA Type 3

CORAL GABLES, Fla., Nov. 21, 2017 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the initiation of a company-sponsored, adequate and well-controlled, proof-of-concept clinical trial evaluating safety, tolerability and… Att fortsätt läsa